抗瘤iRNA、S－TF联合化疗对消化道肿瘤病人LAK、IL－2活性及IL－2R表达的研究

本研究以抗瘤ｉＲＮＡ、Ｓ－ＴＦ与化疗药物单独和联合治疗４６例中晚期消化道肿瘤病人，分别检测各组治疗前后ＬＡＫ、ＩＬ－２活性及ＩＬ－２Ｒ表达等指标变化，并对临床疗效进行了初步观察。结果发现：①单纯化疗组后除ＷＢＣ显著降低外，其它指标均无显著差异；②单纯免疗组治疗后各免疫指标及ＷＢＣ均显著高于治疗前（Ｐ＜０．０５），但症状改善及生存期等则无明显差异；③免疫化疗组治疗后各免疫指标不仅显著高于治疗前，而且亦明显高于化疗组及免疗组其病人症状改善率及３个月、６个月和１年存活率与化疗组化，亦具有显著差异（Ｐ＜０．０５）．本研究提示：抗瘤ｉＲＮＡ及Ｓ－ＴＦ与化疗药物联用优于其单独应用，并在宿主抗肿瘤免疫效应中显示出协同作用。因此，在肿瘤病人化疗时，应提倡联合应用抗瘤ｉＲＮＡ及Ｓ－ＴＦ。

Effects of iRNA,S-TF and Chemotherapy Drugs on LAK Activity,IL-2 Activity and IL-2R Expression in Patients with Advanced Digestive Neoplasms

the effects of chemotherapy drugs alone or combined with iRNA and S-TF on LAK activity,IL-2 activity,IL-2R expression and the survival time of the advanced digestive cancer patients were studied. The results showed that (1) both before and after chemotherapy there were no apparently changes in the clinical and immune indexes, but declined apparently in WBC; (2)the immune indexes and WBC were significantly improved after immunotherapy and immunochemotherapy, and above the indexes in immunochemotherapy group were significantly higher than those in immunotherapy and chemotherapy group respectively; (3)the relief rates and the 3 months, 6 months and 1 year survival rates in immunochemotherapy group were apparently increased when compared to chemotherapy group. We believe that the immunochemotherapy is considerably superior to single-agents chemotherapy or immunotherapy in an synergitical immunoregulation aganist tumor, and therefor administration of iRNA and S-TF should be advocated during chemotherapy.